Nancy El Hoyek

Associate Principal

Nancy El Hoyek advises life sciences and other clients on their HEOR, market access, and evidence generation strategies, with particular focus on oncology and rare disease.

Before joining Avalere, Nancy served as an HEOR field director at Exact Sciences, where she led external HEOR engagements with health systems, policymakers, and payers in the East and Central regions of the United States, to establish the value of Cologuard® using real-world data and economic models. She was responsible for disseminating HEOR evidence and identifying collaborative research opportunities in real-world settings.

Nancy previously held a global HEOR role at Sanofi Genzyme, managing the research and evidence generation plan for rare diseases (Pompe disease and Acid sphingomyelinase deficiency) and covering the big 5 markets (USA, Canada, UK, France, Germany). Nancy also led the market access and pricing function for Merck (known as MSD outside the United States) in the EMEA/Levant region, developing market access and reference pricing mitigation strategies for Keytruda® (pembrolizumab). She has also worked in the regulatory affairs department at MSD, leading the registration and maintenance of marketing authorization applications for the oncology and anti-infective portfolios in the Levant region.

Nancy holds an Msc in Pharmacoeconomics & Health Policy from Massachusetts College of Pharmacy & Health Sciences, in addition to her MBA and Doctor of Pharmacy and Clinical & Hospital Pharmacy degrees from St. Joseph University in Lebanon.

Authored Content

The FDA’s final rule to regulate LDTs as medical devices brings on numerous uncertainties for stakeholders.

With regulatory changes on the horizon, diagnostics stakeholders should prepare for a new evidence development and commercialization environment.